share_log

莫高股份(600543.SH):筹划获取皓天科技51%股权

Mogao Group (600543.SH): Planning to acquire 51% equity of Haotian Technology.

Gelonghui Finance ·  Aug 28 06:39

Geelong August 28th | Moco shares (600543.SH) announced that the company is planning to acquire 51% equity of Gansu Haotian Technology Co., Ltd. ('Haotian Technology' or 'the target company') by means of a combination of cash payment and capital increase. The specific acquisition or equity increase ratio is subject to further demonstration and negotiation. After the completion of this transaction, Haotian Technology is expected to become a subsidiary of the company. This transaction is still in the planning stage. Haotian Technology has voluntarily applied to withdraw the IPO application. The parties to the transaction have not yet signed any agreements on the transaction plan, the scope of the transaction counterpart, the proportion of equity acquisition and capital increase, the transaction price, performance commitments, etc. The core matters of the transaction still need further demonstration and negotiation, and the necessary internal and external related decisions and approval procedures of the company, the target company and the transaction counterpart need to be fulfilled. There is a risk that these decisions and approval procedures may not be passed.

The main business of the target company includes pharmaceutical-related production and manufacturing such as CDMO and adjuvant research and production, which has good synergy with the listed company. After the completion of this transaction, the target company will become a subsidiary of the listed company. It is expected that the business scale of the company will be improved after this transaction, which is conducive to strengthening the overall competitiveness of the company. This transaction is a cash transaction and does not involve the issuance of shares, and does not affect the equity structure of the listed company. This transaction is the company's active expansion of the pharmaceutical business sector, enriching the company's pharmaceutical business sector industry chain and research and development capabilities, which has a positive impact on the company's development and is in line with the interests of the company and small and medium shareholders.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment